Wee1 inhibitors are a promising new cancer treatment, but serious side effects threaten their adoption in the clinic. Now, ...

Publication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid ...

The study, published in Proceedings of the National Academy of Sciences of the United States of America, deepens ...

UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.

Morphological, anatomical and DNA analyses identified the cave-dwelling salifid leech Troglobdella guizhouensis in a single ...

FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.

Rakovina has advanced the program from target specification through lead generation and five cycles of iterative lead optimization in approximately two years, using Variational AI’s Enki™ generative ...

Kiszala, the CEO and co-founder of intoDNA, to explore how a breakthrough in understanding DNA damage and repair could ...

A combined genetic, cellular, and mouse study finds that semaglutide strengthens gemcitabine's antitumor effect by ...

Wee1 inhibitors are a promising new cancer treatment, but serious side effects threaten their adoption in the clinic. Now, researchers from the MRC ...

October 20 is Liver Day, designated by the Korean Liver Foundation and the Korean Association for the Study of the Liver.